Dry eye continues to be a hot spot when it comes to new diagnostic and therapeutic modalities.
Large established companies and small startups alike continue to develop new products and bring them to market. To be sure, some of the new offerings are less new and more “me too.” I mean, how many more different options do we really need in the cyclosporine A space? I would be perfectly content with what we have now if they could just be unshackled from the predation of pharmacy benefit managers.
Still, every (Read more...)